IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 201-225 out of 1250.

<< < 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 > >>

Public Release: 23-Mar-2014
Nature Methods
'MaMTH' advance: New technology sheds light on protein interactions
Scientists have a better way to study human proteins -- large molecules that are part of every cell in the body -- thanks to a new technology developed by University of Toronto researchers. The technology tracks a class of proteins called membrane proteins as they interact with other proteins to either maintain health or contribute to disease.
Ontario Genomics Institute, Canadian Institutes of Health Research, Canadian Cancer Society

Contact: Jim Oldfield
jim.oldfield@utoronto.ca
416-946-8423
University of Toronto

Public Release: 23-Mar-2014
Nature
Leukemia caused by chromosome catastrophe
Researchers have found that people born with a rare abnormality of their chromosomes have a 2,700-fold increased risk of a rare childhood leukemia. In this abnormality, two specific chromosomes are fused together but become prone to catastrophic shattering.
Wellcome Trust, Leukaemia and Lymphoma Research Specialist Programme, FWO, European Research Council

Contact: Mary Clarke
press.office@sanger.ac.uk
44-012-234-95328
Wellcome Trust Sanger Institute

Public Release: 23-Mar-2014
Nature Structural & Molecular Biology
Mass. General study identifies path to safer drugs for heart disease, cancer
Massachusetts General Hospital investigators may have found a way to solve a problem that has plagued a group of drugs called ligand-mimicking integrin inhibitors, which have the potential to treat conditions ranging from heart attacks to cancer metastasis.
NIH/National Institute of Diabetes and Digestive and Kidney Diseases

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital

Public Release: 23-Mar-2014
Society of Gynecological Oncology 45th Annual Meeting on Women's Cancer
HPV eradicated by AHCC supplement, preclinical study suggests
HPV, human papilloma virus, was eradicated by AHCC, a Japanese mushroom extract, in vivo and in vitro, in preclinical research presented by Judith A. Smith, PharmD., at Society of Gynecological Oncology 45th Annual Meeting on Women's Cancer in Tampa. These data suggest AHCC can eliminate HPV infections and may have a role in the prevention of HPV-related cancers. A confirmatory pilot study in HPV+ women is underway at UTHealth Women's Center.

Contact: John Carney or Julie McQuain
JMPRmedia@aol.com
212-477-0472
JMPR Associates, Inc.

Public Release: 23-Mar-2014
Nature Genetics
TGen-led study discovers genetic cause of rare type of ovarian cancer
The cause of a rare type of ovarian cancer that most often strikes girls and young women has been uncovered by an international research team led by the Translational Genomics Research Institute, according to a study published online today by the renowned scientific journal, Nature Genetics. The findings revealed a 'genetic superhighway' mutation in a gene found in the overwhelming majority of patients with small cell carcinoma of the ovary, hypercalcemic type, or SCCOHT.

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute

Public Release: 22-Mar-2014
Society of Gynecology Oncology Annual Conference
Gynecologic Oncology
Bariatric surgery decreases risk of uterine cancer
Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center report that bariatric surgery resulting in dramatic weight loss in formerly severely obese women reduces the risk of endometrial (uterine) cancer by 71 percent and as much as 81 percent if normal weight is maintained after surgery.

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 21-Mar-2014
The 9th European Breast Cancer Conference (EBCC-9)
A third of women might benefit from more frequent mammograms
A study of over 50,000 women participating in the United Kingdom NHS Breast Screening Programme has found that, while three-yearly screening intervals are appropriate for the majority of women, approximately one third of women are at higher risk of developing cancer and might benefit from more frequent mammograms. The research is presented at the 9th European Breast Cancer Conference.
National Institute for Health Research, Genesis Breast Cancer Prevention

Contact: Emma Mason
wordmason@mac.com
ECCO-the European CanCer Organisation

Public Release: 21-Mar-2014
The 9th European Breast Cancer Conference (EBCC-9)
Significant variations between NHS hospitals in adverse outcomes for treatment of DCIS
Analysis of data from the United Kingdom NHS Breast Screening Programme has shown significant variations in the outcomes of treatment for women with ductal carcinoma in situ between United Kingdom hospitals, according to research presented at the European Breast Cancer Conference.
NHS Breast Screening Programme, Public Health England

Contact: Emma Mason
wordmason@mac.com
ECCO-the European CanCer Organisation

Public Release: 21-Mar-2014
The 9th European Breast Cancer Conference (EBCC-9)
Harms outweigh benefits for women aged 70 and over in national breast cancer screening programs
Extending national breast cancer screening programs to women over the age of 70 does not result in a decrease in the numbers of cancers detected at advanced stages, according to new research from the Netherlands.

Contact: Emma Mason
wordmason@mac.com
ECCO-the European CanCer Organisation

Public Release: 21-Mar-2014
Journal of National Cancer Institute
New method can diagnose a feared form of cancer
Pancreatic cancer is often detected at a late stage, which results in poor prognosis and limited treatment options. Researchers at The University of Gothenburg, Sweden, have now developed a method which identifies the cancer's visible precursors with 97 percent certainty. The method, which is expected to aid in the early discovery of the cancer as well as minimize the risk of unnecessary surgery, may be introduced in patient care within five years.

Contact: Karolina Jabbar
karolina.sjoberg@medkem.gu.se
46-317-863-861
University of Gothenburg

Public Release: 21-Mar-2014
Journal of Thoracic Oncology
Characteristics of lung cancers arising in germline EGFR T790M mutation carriers
Two studies are providing new insight into germline epidermal growth factor receptor T790M mutation in familial non-small cell lung cancer. The findings suggest the need for tailored approaches for early detection and treatment, as well as for genetic testing to identify carriers.

Contact: Kristin Richeimer
kristin.richeimer@iaslc.org
720-325-2953
International Association for the Study of Lung Cancer

Public Release: 21-Mar-2014
Journal of Clinical Oncology
Keck Medicine of USC research may point to better predictor of prostate cancer survival
New research by USC Norris Comprehensive Cancer Center scientists demonstrates that measuring circulating tumor cells -- the cells that spread cancer through the body -- may be a better predictor of patient survival than the prostate-specific antigen.
NIH/National Cancer Institute, Hope Foundation

Contact: Leslie Ridgeway
lridgewa@usc.edu
323-442-2823
University of Southern California - Health Sciences

Public Release: 20-Mar-2014
Gastroenterology
Colonoscopy isn't perfect: About 6 percent of colorectal cancers are missed
About 6 percent of colorectal cancers are diagnosed within three to five years after the patient receives a clean colonoscopy report, according to a population-based study by researchers from Huntsman Cancer Institute at the University of Utah.
Huntsman Cancer Institute, NIH/National Cancer Institute

Contact: Linda Aagard
801-587-7639
University of Utah Health Sciences

Public Release: 20-Mar-2014
The 9th European Breast Cancer Conference (EBCC-9)
Deaths from breast cancer fall in Europe
Improvements in treatment, as well as enhanced access to care, underlie the sustained decreases in breast cancer mortality seen in 30 European countries from 1989 to 2010. But there are notable variations between different countries that cannot be explained simply by the resources devoted to cancer care, and these differences need to be studied further.

Contact: Mary Rice
mary.rice@riceconseil.eu
ECCO-the European CanCer Organisation

Public Release: 20-Mar-2014
The 9th European Breast Cancer Conference (EBCC-9)
Regular physical activity reduces breast cancer risk irrespective of age
Practicing sport for more than an hour day reduces the risk of contracting breast cancer, and this applies to women of any age and any weight, and also unaffected by geographical location, according to research presented to the 9th European Breast Cancer Conference. Compared with the least active women, those with the highest level of physical activity reduced their risk of breast cancer by 12 percent, researchers say.

Contact: Mary Rice
mary.rice@riceconseil.eu
ECCO-the European CanCer Organisation

Public Release: 20-Mar-2014
American Journal of Human Genetics
New tool pinpoints genetic sources of disease
Many diseases have their origins in either the genome or in reversible chemical changes to DNA known as the epigenome. Now, results of a new study from Johns Hopkins scientists show a connection between these two 'maps.' The findings, reported March 20 in the American Journal of Human Genetics, could help disease trackers find patterns that offer clues to the causes of and possible treatments for complex genetic conditions, including many cancers and metabolic disorders.
NIH/National Human Genome Research Institute, NIH/National Institute on Aging, Swedish AFA Insurance, Swedish Foundation for Strategic Research, European Research Council

Contact: Shawna Williams
shawna@jhmi.edu
410-955-8236
Johns Hopkins Medicine

Public Release: 20-Mar-2014
The 9th European Breast Cancer Conference (EBCC-9)
Obesity and diabetes have adverse effects on cancer outcomes
Both obesity and diabetes have adverse effects on outcomes in breast cancer patients who receive chemotherapy as primary treatment before surgery, according to research to be presented at the 9th European Breast Cancer Conference on March 21. Although a high body mass index is known to have a negative impact on cancer development and prognosis, until now there has been uncertainty as to whether having a high body mass index had an equal effect on patients with different types of breast tumors.

Contact: Mary Rice
mary.rice@riceconseil.eu
ECCO-the European CanCer Organisation

Public Release: 20-Mar-2014
Immunity
Institut Pasteur and Myriad RBM publish results from landmark study of immune response
Institut Pasteur and Myriad RBM, a wholly-owned subsidiary of Myriad Genetics, Inc., today announced they have published an initial data analysis from the landmark Milieu Interieur Project in the journal Immunity, which provided new insights into the healthy human immune response. The Milieu Interieur project will characterize the immune phenotypes of 1,000 healthy subjects. The results could lead to the development of novel diagnostics and companion diagnostics.

Contact: Ron Rogres
rrogers@myriad.com
801-584-3065
Myriad Genetics, Inc.

Public Release: 20-Mar-2014
Stem Cell Reports
Stem cell study finds source of earliest blood cells during development
In a study published April 8 in Stem Cell Reports, Matthew Inlay of the Sue & Bill Gross Stem Cell Research Center and Stanford University colleagues created novel cell assays that identified the earliest arising HSC precursors based on their ability to generate all major blood cell types (red blood cells, platelets and immune cells).
National Institutes of Health

Contact: Matthew Inlay
minlay@uci.edu
949-824-8226
University of California - Irvine

Public Release: 20-Mar-2014
Cancer Immunology Research
Potential lung cancer vaccine shows renewed promise
Researchers at UC Davis have found that the investigational cancer vaccine tecemotide, when administered with the chemotherapeutic cisplatin, boosted immune response and reduced the number of tumors in mice with lung cancer.
Merck KGaA

Contact: Dorsey Griffith
dorsey.griffith@ucdmc.ucdavis.edu
916-734-9118
University of California - Davis Health System

Public Release: 20-Mar-2014
Cell Reports
Surprising new way to kill cancer cells
Scientists have demonstrated that cancer cells -- and not normal cells -- can be killed by eliminating either the FAS receptor, also known as CD95, or its binding component, CD95 ligand. The discovery seems counterintuitive because CD95 has previously been defined as a tumor suppressor, scientists said.
NIH/National Cancer Institute

Contact: Marla Paul
marla-paul@northwestern.edu
312-503-8928
Northwestern University

Public Release: 20-Mar-2014
Cell Stem Cell
Proteins that control energy use necessary to form stem cells
Two proteins that control how cells metabolize glucose play a key role in the formation of human stem cells. Studies suggest these proteins which also play a role in the process that transforms normal cells into cancer stem cells, might also be targets for new cancer therapies.
American Heart Association, Tietze Award, National Institutes of Health

Contact: Kim Blakeley
krb13@uw.edu
206-685-1323
University of Washington - Health Sciences/UW News, Community Relations & Marketing

Public Release: 20-Mar-2014
Journal of Clinical Investigation
Inhibition of CDK4 might promote lymphoma development and progression
Anticancer agents that inhibit tumor growth by targeting a cell-cycle regulatory protein called CDK4 might actually promote the development and progression of certain B-cell lymphomas. The research suggests that CDK4 inhibitors, which are now in clinical testing, should be used cautiously, particularly in patients with B-cell lymphomas. The findings raise the possibility that these inhibitors work through off-target effects and require further investigation.
NIH/National Cancer Institute

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Wexner Medical Center

Public Release: 20-Mar-2014
Cancer Cell
Study reveals a major mechanism driving kidney cancer progression
The shortage of oxygen, or hypoxia, created when rapidly multiplying kidney cancer cells outgrow their local blood supply can accelerate tumor growth by causing a nuclear protein called SPOP -- which normally suppresses tumor growth -- to move out of the nucleus to the cytoplasm, where it has the opposite effect, promoting rapid proliferation. This cytoplasmic accumulation of SPOP is sufficient to convey tumorigenic properties onto otherwise non-tumorigenic cells.
National Institutes of Health, Beijing Science Foundation, Keck Foundation, Chicago Community Trust, Chicago Biomedical Consortium

Contact: John Easton
john.easton@uchospitals.edu
773-795-5225
University of Chicago Medical Center

Public Release: 20-Mar-2014
Molecular Cell
Gene silencing instructions acquired through 'molecular memory' tags on chromatin
Scientists at Indiana University have unlocked one of the mysteries of modern genetics: how acquired traits can be passed between generations in a process called epigenetic inheritance.

Contact: Steve Chaplin
stjchap@iu.edu
812-856-1896
Indiana University

Showing releases 201-225 out of 1250.

<< < 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 > >>

  Search News Releases

     

 

 

EurekAlert!